Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Research

Analysis of HAX-1 gene expression in esophageal squamous cell carcinoma

Authors: Min Li, Yue Tang, Wenqiao Zang, Xiaoyan Xuan, Na Wang, Yunyun Ma, Yuanyuan Wang, Ziming Dong, Guoqiang Zhao

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Objective

To explore the expression of HAX-1 mRNA and protein in esophageal squamous cell carcinoma (ESCC) and its relation with the prognosis of patients with ESCC.

Methods

The expression of HAX-1 mRNA and protein were detected with quantitative real-time RT-PCR and immunohistochemical method in 112 ESCC samples and 112 corresponding non-neoplastic samples. Survival curves were made with follow-up data. The relations of the prognosis with clinical and pathological characteristics were analyzed.

Results

The expression level of HAX-1 mRNA and the strong positive rate of HAX-1 protein were significantly higher in ESCC samples (0.527 ± 0.060 and 45.54%) than that in non-neoplastic samples (0.121 ± 0.017 and 0.00%), and in ESCC samples with lymph node metastasis (0.554 ± 0.054 and 71.11%) than that in ESCC samples without lymph node metastasis (0.509 ± 0.058 and 28.36%) (all P < 0.01). HAX-1 mRNA expression level was a risk factor of lymph node metastasis in patients with ESCC (P = 0.000). There were significant differences in survival curves between lymph node metastatic group and non-metastatic group (P = 0.000), and among groups of HAX-1 protein expression +, ++and +++(,P = 0.000); but no statistical significance between male patients and female patients (P = 0.119), and between ≥60 years old patients and <60 years old patients (P = 0.705). The level of HAX-1 mRNA (P = 0.000) and protein (P = 0.005) were risk factors of survival, but lymph node metastasis (P = 0.477) was not.

Conclusion

There is HAX-1 over-expression in ESCC tissue and HAX-1 mRNA level is a risk factor of lymph node metastasis. The level of HAX-1 mRNA and protein were risk factors of survival in patients with ESCC. HAX-1 may be a novel therapeutic target for ESCC treatment.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​5130393079296037​
Appendix
Available only for authorised users
Literature
1.
Suzuki Y, Demoliere C, Kitamura D, Takeshita H, Deuschle U, Watanabe T: HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol. 1997, 158: 2736-2744.PubMed
2.
Carlsson G, van’t Hooft I, Melin M, Entesarian M, Laurencikas E, Nennesmo I, Trebińska A, Grzybowska E, Palmblad J, Dahl N, Nordenskjöld M, Fadeel B, Henter JI: Central nervous system involvement in severe congenital neutropenia: neurological and neuropsychological abnormalities associated with specific HAX1 mutations. J Intern Med. 2008, 264: 388-400. 10.1111/j.1365-2796.2008.01982.x.CrossRefPubMed
3.
Fadeel B, Grzybowska E: HAX-1: a multifunctional protein with emerging roles in human disease [J]. Biochim Biophys Acta. 2009, 1790: 1139-1148. 10.1016/j.bbagen.2009.06.004.CrossRefPubMed
4.
Chao JR, Parganas E, Boyd K, Hong CY, Opferman JT, Ihle JN: Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons. Nature. 2008, 452: 98-102. 10.1038/nature06604.CrossRefPubMed
5.
Sharp TV, Wang HW, Koumi A, Hollyman D, Endo Y, Ye H, Du MQ, Boshoff C: K15 protein of Kaposi’s sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol. 2002, 76: 802-816. 10.1128/JVI.76.2.802-816.2002.PubMedCentralCrossRefPubMed
6.
Han Y, Chen YS, Liu Z, Bodyak N, Rigor D, Bisping E, Pu WT, Kang PM: Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition. Circ Res. 2006, 99: 415-423. 10.1161/01.RES.0000237387.05259.a5.CrossRefPubMed
7.
Cilenti L, Soundarapandian MM, Kyriazis GA, Stratico V, Singh S, Gupta S, Bonventre JV, Alnemri ES, Zervos AS: Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem. 2004, 79: 50295-50301.CrossRef
8.
Lee AY, Lee Y, Park YK, Bae KH, Cho S, Lee do H, Park BC, Kang S, Park SG: HS1-associated protein X-1 is cleaved by caspase-3 during apoptosis. Mol Cells. 2008, 25: 86-90.PubMed
9.
Vafiadaki E, Arvanitis DA, Pagakis SN, Papalouka V, Sanoudou D, Kontrogianni-Konstantopoulos A, Kranias EG: The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival. Mol Biol Cell. 2009, 20: 306-318. 10.1091/mbc.E08-06-0587.PubMedCentralCrossRefPubMed
10.
Yedavalli VS, Shih HM, Chiang YP, Lu CY, Chang LY, Chen MY, Chuang CY, Dayton AI, Jeang KT, Huang LM: Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J Virol. 2005, 79: 13735-13746. 10.1128/JVI.79.21.13735-13746.2005.PubMedCentralCrossRefPubMed
11.
Shaw J, Kimheubaum LA: HAX-1 represses postmitochondrial caspase-9 activation and cell death during hypoxia-reoxygenation. Circ Res. 2006, 99: 336-338. 10.1161/01.RES.0000239408.03169.94.CrossRefPubMed
12.
Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, Violette S, Weinreb P, Hart IR, Marshall JF: HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res. 2007, 67: 5275-5284. 10.1158/0008-5472.CAN-07-0318.CrossRefPubMed
13.
Radhika V, Onesime D, Ha JH, Dhanasekaran N: Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1. J Biol Chem. 2004, 279: 49406-49413. 10.1074/jbc.M408836200.CrossRefPubMed
14.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004, 6: 1-6.PubMedCentralCrossRefPubMed
15.
Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, Madden SL, Kaelin WG, Nacht M: Gene expression profiling in a renal cell carcinoma cell line: Dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res. 2003, 1: 453-462.PubMed
16.
Mirmohammadsadegh A, Tartler U, Michel G, Baer A, Walz M, Wolf R, Ruzicka T, Hengge UR: HAX-1, identified by differential display reverse transcription polymerase chain reaction, is overexpressed in lesional psoriasis. J Invest Dermatol. 2003, 120: 1045-1051. 10.1046/j.1523-1747.2003.12247.x.CrossRefPubMed
17.
Trebinska A, Rembiszewska A, Ciosek K, Ptaszynski K, Rowinski S, Kupryjanczyk J, Siedlecki JA, Grzybowska EA: HAX-1 overexpression, splicing and cellular localization in tumors. BMC Cancer. 2010, 10: 76-10.1186/1471-2407-10-76.PubMedCentralCrossRefPubMed
18.
Banerjee A, Saito K, Meyer K, Banerjee S, Ait-Goughoulte M, Ray RB, Ray R: Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition. J Virol. 2009, 83: 9663-9671. 10.1128/JVI.00872-09.PubMedCentralCrossRefPubMed
19.
Simmen T: Hax-1: a regulator of calcium signaling and apoptosis progression with multiple roles in human disease. Expert Opin Ther Targets. 2011, 15: 741-751. 10.1517/14728222.2011.561787.CrossRefPubMed
20.
Li WB, Feng J, Geng SM, Zhang PY, Yan XN, Hu G, Zhang CQ, Shi BJ: Induction of apoptosis by Hax-1 siRNA in melanoma cells. Cell Biol Int. 2009, 33: 548-554. 10.1016/j.cellbi.2009.02.005.CrossRefPubMed
21.
Szwarc M, Sarnowska E, Grzybowska EA: HAX-1 protein: multifunctional factor involved in apoptosis, cell migration, endocytosis and mRNA transport. Postepy Biochem. 2007, 53: 218-227.PubMed
22.
Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X: ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagnostic Pathology. 2012, 7: 180-10.1186/1746-1596-7-180.PubMedCentralCrossRefPubMed
23.
Sun SJ, Feng L, Zhao GQ, Dong ZM: HAX-1 promotes the chemoresistance, invasion, and tumorigenicity of esophageal squamous carcinoma cells. Dig Dis Sci. 2012, 57: 1838-1846. 10.1007/s10620-012-2108-5.CrossRefPubMed
Metadata
Title
Analysis of HAX-1 gene expression in esophageal squamous cell carcinoma
Authors
Min Li
Yue Tang
Wenqiao Zang
Xiaoyan Xuan
Na Wang
Yunyun Ma
Yuanyuan Wang
Ziming Dong
Guoqiang Zhao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-47

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue

Research

Histological subtypes and characteristic structures of HPV-associated oropharyngeal carcinoma; study with Japanese cases

Software

Open source tools for management and archiving of digital microscopy data to allow integration with patient pathology and treatment information

Case Report

Paratesticular dedifferentiated liposarcoma with leiomyosarcomatous differentiation: a case report with a review of literature

Research

The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer

Case Report

RETRACTED ARTICLE: Ulnar malignant peripheral nerve sheath tumour diagnosis in a mixed-breed dog as a model to study human: histologic, immunohistochemical, and clinicopathologic study

Case Report

Sudden death of an infant with cardiac, nervous system and genetic involvement – a case report